| Literature DB >> 35020094 |
Angela Kaida1,2, Lori A Brotto3,4, Melanie C M Murray3,4,5, Hélène C F Côté3,4, Arianne Y Albert3, Valerie Nicholson6,7, Rebecca Gormley6,7, Shanlea Gordon3, Amy Booth3,4, Laurie W Smith3,8, Ally Baaske3, Liisa A M Galea3,4, Manish Sadarangani4,9, Gina S Ogilvie3,4,10.
Abstract
COVID-19 vaccination is recommended for people living with HIV (PLWH), among whom social inequities and co-morbidities may drive risks of COVID-19 infection and outcome severity. Among a provincial (British Columbia) sample, we determined the prevalence of COVID-19 vaccine intention by HIV status and assessed socio-demographic, vaccine hesitancy, and psychological predictors of vaccine intention. Individuals (25-69 years) recruited from province-wide research cohorts and the general public completed an online survey examining COVID-19 impacts (August/2020-March/2021). In an analysis restricted to women and gender diverse participants (n = 5588), we compared intention to receive a recommended COVID-19 vaccine (Very likely/Likely vs Neutral/Unlikely/Very Unlikely) by self-reported HIV status. Logistic regression models assessed the independent effect of HIV status and other factors on COVID-19 vaccine intention. Of 5588 participants, 69 (1.2%) were living with HIV, of whom 79.7% were on antiretroviral therapy. In bivariate analyses, intention to vaccinate was significantly lower among PLWH compared to participants not living with HIV (65.2% vs 79.6%; OR 0.44; 95%CI 0.32-0.60). However, this association was not statistically significant after adjustment for ethnicity, income, education, and essential worker status (aOR 0.85; 95%CI 0.48-1.55). Among PLWH, those with greater vaccine confidence, positive attitudes towards the COVID-19 vaccine, and more strongly influenced by direct and indirect social norms to vaccinate had significantly higher odds of vaccine intention. Tailored messaging is needed to build vaccine confidence, address questions about vaccine benefits, and support informed vaccination decision-making to promote COVID-19 vaccine uptake among women and gender diverse people living with HIV.Entities:
Keywords: COVID-19 vaccine; Gender diverse populations; HIV; Intention to vaccinate; Social determinants of health; Vaccine hesitancy; Women
Mesh:
Substances:
Year: 2022 PMID: 35020094 PMCID: PMC8753016 DOI: 10.1007/s10461-022-03577-w
Source DB: PubMed Journal: AIDS Behav ISSN: 1090-7165
Vaccine Hesitancy and COVID-19 vaccine Psychological Constructs by HIV status, column %
| Mean score (SD) overall | Scale alpha (standardized) | Not living with HIV (n = 5519) | Living with HIV | Test-statistic | p value | |
|---|---|---|---|---|---|---|
| 1.3 (± 0.6) | 0.949 | 1.3 (± 0.6) | 1.6 (± 1.1) | W = 151,584 | ||
| Missing | 40 (0.7%) | 38 (0.7%) | 2 (2.9%) | |||
| Childhood vaccines are important for a child’s health | 3% | 12% | Χ2 = 26.43 | |||
| Getting vaccines is a good way to protect children from disease | 3% | 12% | Χ2 = 28.89 | |||
| Having a child vaccinated is important for the health of others in my community | 3% | 13% | Χ2 = 26.65 | |||
| Childhood vaccines are effective (VHS 3) | 3% | 14% | Χ2 = 33.32 | |||
| Generally, I do what my doctor or health care provider recommends about vaccines | 8% | 16% | Χ2 = 37.67 | |||
| All childhood vaccines offered by the BC immunization program in my community are beneficial | 8% | 19% | Χ2 = 29.98 | |||
| The information I receive about vaccines from the vaccination program is reliable and trustworthy | 12% | 19% | Χ2 = 17.20 | |||
Bold values indicate the p-value is < 0.05 and the result is statistically significant
Baseline characteristics of study sample overall and by HIV status, column % (n = 5588)
| Total | HIV status | ||||
|---|---|---|---|---|---|
| Not living with HIV | Living with HIV | Test statistic | p value | ||
| n = 5588 | (n=5519) | (n=69) | |||
| Age Mean (SD) | 48.2 (±12.1) | 48.1 (±12.1) | 49.9 (±11.4) | W = 176592 | 0.30 |
| Female | 5565 (99.6%) | 5499 (99.6%) | 66 (95.7%) | Χ2 = 25.34 | 0.001 |
| Male | 17 (0.3%) | 14 (0.3%) | 3 (4.3%) | ||
| Woman | 5,514 (98.7%) | 5,451 (98.8%) | 63 (91.3%) | Χ2 = 23.62 | 0.0003 |
| Gender diverse (non-binary, GenderQueer, agender, Two-spirit, gender fluid, or other gender identity) | 74 (1.3%) | 68 (1.2%) | 6 (8.7%) | ||
| Χ2 = 266.69 | < 0.0001 | ||||
| Indigenous | 186 (3.3%) | 166 (3.0%) | 20 (29.0%) | ||
| African/Caribbean/Black | 21 (0.4%) | 15 (0.3%) | 6 (8.7%) | ||
| White | 4,441 (79.5%) | 4,402 (79.8%) | 39 (56.5%) | ||
| Other or mixed ethnicity | 775 (13.9%) | 771 (14.0%) | 4 (5.8%) | ||
| 4,879 (87.3%) | 4,834 (87.6%) | 45 (65.2%) | Χ2 = 29.54 | <0.0001 | |
| 138 (2.5%) | 126 (2.3%) | 12 (17.4%) | Χ2 = 266.69 | < 0.0001 | |
| None | 2792 (50.0%) | 2780 (50.4%) | 12 (17.4%) | Χ2 = 45.38 | < 0.0001 |
| 1 | 1538 (27.5%) | 1518 (27.5%) | 20 (29.0%) | ||
| 2+ | 1249 (22.4%) | 1212 (22.0%) | 37 (53.6%) | ||
| No | 3752 (67.1%) | 3702 (67.1%) | 50 (72.5%) | Χ2 = 2.47 | 0.30 |
| Yes, health worker | 865 (15.5%) | 859 (15.6%) | 6 (8.7%) | ||
| Yes, other essential worker | 967 (17.3%) | 954 (17.3%) | 13 (18.8%) | ||
Baseline characteristics of people living with HIV enrolled in the RESPPONSE study (n = 69)
| Characteristic | n or Median | % or IQR |
|---|---|---|
| Median years living with HIV | 20.5 | 14.0–17.0 |
| Currently on antiretroviral therapy (ART) | 55 | 79.7% |
| Median years on ART | 14.0 | 10.0–23.0 |
| Undetectable HIV viral load (< 50 copies/mL) | 51 | 73.9% |
| Received any HIV medical care since COVID-19 restrictions | 43 | 62.3% |
| More/much more fearful | 34 | 58.6% |
| It makes no difference | 22 | 37.9% |
| Less/much less fearful | 2 | 3.4% |
Unadjusted and adjusted odds ratios (and 95% confidence intervals) of vaccine intention by HIV status and socio-demographic variables, row %
| Intention to receive the COVID-19 vaccine | Unadjusted odds ratio (OR) | Adjusted odds ratio (aOR) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | No | Yes | Test | p value | Crude | 95%CI | p value | Adjusted | 95% CI | p value | |
| n = 5568 | n = 1129 | n = 4439 | Statistic§ | OR | OR | ||||||
| Not living with HIV | 5500 (98.8%) | 1106 (20.0%) | 4394 (79.6%) | 6.87 | Ref | Ref | Ref | Ref | 0.576 | ||
| Living with HIV | 68 (1.2%) | 23 (33.3%) | 45 (65.2%) | 0.49 | 0.30–0.83 | 0.85 | 0.48–1.55 | ||||
| Mean (± SD) | 48.2 (± 12.1) | 48.1 (± 11.0) | 48.2 (± 12.3) | 0.03 | 0.86 | 1.00 | 1.00–1.01 | 0.863 | 1.00 | 0.99–1.01 | 0.763 |
| Woman | 5494 (98.7%) | 1118 (20.3%) | 4376 (79.7%) | 1.46 | 0.31 | Ref | Ref | 0.25 | Not included | ||
| Gender diverse | 74 (1.3%) | 11 (14.9%) | 63 (85.1%) | 1.46 | 0.80–2.94 | ||||||
| White | 4427 (79.5%) | 847 (19.1%) | 3580 (80.9%) | 32.39 | Ref | Ref | Ref | Ref | |||
| Other or mixed | 770 (13.8%) | 171 (22.2%) | 599 (77.8%) | 0.83 | 0.69–1.00 | 0.76 | 0.62–0.94 | ||||
| Indigenous | 186 (3.3%) | 65 (34.9%) | 121 (65.1%) | 0.44 | 0.32–0.60 | 0.49 | 0.35–0.70 | ||||
| African/Caribbean/Black | 21 (0.4%) | 9 (42.9%) | 12 (57.1%) | 0.32 | 0.13–0.78 | 0.49 | 0.19–1.38 | 0.153 | |||
| Missing | 164 (2.9%) | 37 (22.6%) | 127 (77.4%) | ||||||||
| More than high school | 4864 (87.4%) | 926 (19.0%) | 3938 (81.0%) | 35.23 | Ref | Ref | Ref | Ref | |||
| High school or less | 694 (12.5%) | 202 (29.1%) | 492 (70.9%) | 0.57 | 0.48–0.69 | 0.65 | 0.53–0.79 | ||||
| Missing | 10 (0.2%) | 1 (10.0%) | 9 (90.0%) | ||||||||
| $80K+ | 3049 (54.8%) | 516 (16.9%) | 2533 (83.1%) | 58.54 | Ref | Ref | Ref | Ref | |||
| 0 to < $40K | 424 (7.6%) | 131 (30.9%) | 293 (69.1%) | 0.46 | 0.36–0.57 | 0.53 | 0.42—0.67 | ||||
| $40 K to < $80 K | 962 (17.3%) | 215 (22.3%) | 747 (77.7%) | 0.71 | 0.59–0.85 | 0.77 | 0.64—0.92 | ||||
| Don't know/no response | 1133 (20.3%) | 267 (23.6%) | 866 (76.4%) | 0.66 | 0.56–0.78 | 0.69 | 0.58—0.82 | ||||
| None | 2,780 (49.9%) | 575 (20.7%) | 2,205 (79.3%) | 1.70 | 0.43 | Ref | Ref | Not included | |||
| 1 | 1536 (27.6%) | 294 (19.1%) | 1242 (80.9%) | 1.10 | 0.94–1.29 | 0.226 | |||||
| 2 + | 1243 (22.3%) | 258 (20.8%) | 985 (79.2%) | 1.00 | 0.84–1.18 | 0.958 | |||||
| Missing | 9 (0.2%) | 2 (22.2%) | 7 (77.8%) | ||||||||
| No | 3739 (67.2%) | 736 (19.7%) | 3003 (80.3%) | 28.21 | Ref | Ref | Ref | Ref | |||
| Yes, health worker | 860 (15.4%) | 140 (16.3%) | 720 (83.7%) | 1.26 | 1.04–1.54 | 1.13 | 0.91–1.41 | 0.278 | |||
| Yes, other essential worker | 965 (17.3%) | 251 (26.0%) | 714 (74.0%) | 0.70 | 0.59–0.82 | 0.69 | 0.57–0.83 | ||||
| Missing | 4 (0.1%) | 2 (50.0%) | 2 (50.0%) | ||||||||
§Likelihood Ratio Test Statistic
Bold values indicate the p-value is < 0.05 and the result is statistically significant
Bivariable associations between socio-demographic, vaccine hesitancy, and psychological constructs and intention to receive the COVID-19 vaccine among women and gender diverse individuals living with HIV (n = 69)
| Crude OR | 95% CI | p value | |
|---|---|---|---|
| Age (per year increase) | 1.05 | 1.00–1.10 | |
| No | Ref | Ref | |
| Yes | 0.38 | 0.12–1.19 | 0.10 |
| No (White) | Ref | Ref | |
| Yes (Indigenous, African/Caribbean/Black, Other/mixed ethnicity) | 0.63 | 0.20–2.03 | 0.43 |
| More than High School | Ref | Ref | |
| High School or less | 0.40 | 0.14–1.13 | 0.09 |
| $20K + per year | Ref | Ref | |
| < $20K per year | 0.43 | 0.11–1.62 | 0.21 |
| Don't know/no answer | 0.71 | 0.15–3.93 | 0.68 |
| None | Ref | Ref | |
| 1 or more | 3.50 | 0.98–13.4 | |
| No | Ref | Ref | |
| Yes, health worker | 0.44 | 0.07–2.62 | 0.35 |
| Yes, other essential worker | 0.71 | 0.20–2.66 | 0.59 |
| WHO Lack of Vaccine Confidence Scale | 0.40 | 0.18–0.71 | |
| WHO Vaccine Risks Scale | 0.69 | 0.41–1.11 | 0.141 |
| Attitudes toward the COVID-19 Vaccine Scale | 1.31 | 1.15–1.54 | |
| Perceived Behavioral Control Scale | 1.23 | 1.00–1.53 | 0.058 |
| Direct Social Norms Scale | 1.27 | 1.08–1.54 | |
| Indirect Social Norms: Total Scale | 1.16 | 1.09–1.28 | |
| Indirect Social Norms: Family Doctor/Primary Healthcare Provider | 1.31 | 1.13–1.55 | |
| Indirect Social Norms: BC Provincial Health Officer | 1.74 | 1.36–2.48 | |
| Indirect Social Norms: Friends | 1.58 | 1.25–2.20 | |
| Indirect Social Norms: Family | 1.65 | 1.32–2.25 |
Bold values indicate the p-value is < 0.05 and the result is statistically significant